New pill shows promise for rare cancers in early trial

NCT ID NCT03600233

First seen Jan 09, 2026 · Last updated Apr 30, 2026 · Updated 17 times

Summary

This study tests a new oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The goal is to see if the drug can slow tumor growth or shrink tumors. Participants take the drug by mouth, and their tumors are checked every 12 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chang Gung Memorial Hospital, KaoHsiung

    Kaohsiung City, Taiwan

  • Chang Gung Memorial Hospital, LinKou

    Taoyuan, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • Kaohsiung Medical University Hospital

    Kaohsiung City, Taiwan

  • National Cheng Kung University Hospital

    Tainan, 704, Taiwan

  • New Taipei Municipal TuCheng Hospital

    New Taipei City, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Conditions

Explore the condition pages connected to this study.